| Lipids Management |
1 |
1 |
| PCSK9 |
0 |
0.8 |
| Muscle |
0 |
0.53 |
| Statins |
0 |
0.44 |
| Muscle Spasm |
0 |
0.38 |
| Myalgia |
0 |
0.34 |
| Skeletal Myoblasts |
0 |
0.34 |
| Cardiovascular Risk Management |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Clinical Research |
0 |
0.06 |
| LDL Cholesterol |
0 |
0.04 |
| Pain Management |
0 |
0.04 |
| Lipoproteins |
0 |
0.03 |
| Skeletal |
0 |
0.03 |
| Coronary Artery Disease (CAD) |
0 |
0.02 |
| Pennsylvania |
0 |
0.02 |
| Board Certification |
0 |
0.01 |
| Cardiovascular disease |
0 |
0.01 |
| Familial Hypercholesterolemia |
0 |
0.01 |
| Food and Drug Administration (FDA) |
0 |
0.01 |
| Genetics |
0 |
0.01 |
| Genomic Medicine |
0 |
0.01 |
| Heart |
0 |
0.01 |
| Hypercholesterolemia |
0 |
0.01 |
| Pain |
0 |
0.01 |
| Patient History |
0 |
0.01 |
| Rhabdomyolysis |
0 |
0.01 |
| Statistics |
0 |
0.01 |
| Structured Treatment Interruption |
0 |
0.01 |
| Weakness |
0 |
0.01 |